Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of intravitreal OCUL101 in nAMD, DME, and geographic atrophy
CTR20250853Phase 2Active
- Sponsor
- OculusGen Biomedical
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of OCUL101 in exudative macular degeneration, diabetic macular edema (DME), age-related macular degeneration (AMD), sponsored by OculusGen Biomedical. Started Apr 2025; status: active.
02
Drugs
OCUL101
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on CTR20250853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250853.